© PHARMED CANADA

CONFÉRENCIERS 2016

​Jennifer Hamilton

Jennifer Hamilton is the Senior Director, New Ventures at Johnson & Johnson Innovation. Formerly, she was an Adviser to J&J Innovation where she was responsible for scouting opportunities in Canada.  Prior to that, Jennifer spent 10 years as Venture Partner at UK-based Nomura Phase4 Ventures, an international life sciences fund.   She has worked as an adviser to early and late-stage companies, venture funds and pension funds giving financing, business development and M&A advice. Jennifer has an MSc and a PhD in Experimental Pathology/Lipid Metabolism from the University of British.

Josh Richardson

Dr. Richardson is a Principal at Longitude Capital. Previously, he was with Longitude Capital from 2011 to 2014, and prior to re-joining Longitude Capital in 2016, Dr. Richardson was a Public Equities Analyst at HealthCor Management where he managed small and mid-cap biotechnology investments. Prior to joining Longitude in 2011, Dr. Richardson was an Engagement Manager with McKinsey & Company. Dr. Richardson is a board observer at InfaCare Pharmaceuticals. Dr. Richardson holds an M.D. from the University of Virginia and a B.S. in biomedical science from the University of South Florida.

Amyn Sayani

Dr. Amyn Sayani is the Director of R&D Alliances at GlaxoSmithKline Canada.  In this role, Amyn is responsible for identifying and establishing new R&D collaborations through innovation centres and academic institutions from across Canada to support growth of GSK's early stage pipeline. Amyn has worked in the pharmaceutical industry for over 15 years and has developed a breadth and depth of experience, working in pharmaceutical product development, regulatory affairs and medical affairs.  Amyn is a pharmacist by training, and has a PhD in Pharmaceutical Sciences from Rutgers University in NJ, USA.

Ajit Singh

Ajit Singh is Managing Director and General Partner at Artiman Ventures, a California base venture capital firm focused on early stage "white space" investments. He focuses on early-stage Technology & Life Science investments, and currently represents Artiman on the Boards of Aditazz, CardioDx, Click Diagnostics, CORE Diagnostics, medECUBE and OncoStem. Ajit is also a Consulting Professor in the School of Medicine at Stanford University and serves on the Board of Directors of Max Healthcare based in New Delhi, India. Ajit has a Ph.D. in Computer Science from Columbia University and a master's degree in Computer Engineering from Syracuse University .

Alex Zisson

Alex joined H.I.G. Capital as Managing Director in January 2016. He focuses on investments in the biopharma industry, especially in pharmaceuticals, generics, drug delivery, specialty pharma and biotechnology.  He currently serves on the board of directors for Clarus Therapeutics and Keystone Dental. Prior to H.I.G., he spent 13 years making similar investments at Thomas, McNerney & Partners. Alex is the co-chair of the Business Advisory Council of the Children’s Tumor Foundation, an advisor for the Partnership Fund of NYC, which manages a bioaccelarator to advance local healthcare research. He graduated magna cum laude from Brown University.

Kelly Holman

Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $300 million of venture capital and has been instrumental in deploying over $160 million across 28 investments. 

 

Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corp. During his tenure at MDS, he was involved in all stages of investment from start-up and early-stage to mezzanine stage and public company investing.

 

Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen's University.

​Caroline Stout

Caroline is an investor at EcoR1 Capital, a biotechnology-focused investment fund in San Francisco. Prior to joining EcoR1 Capital, Caroline worked as an investment banker at Credit Suisse in New York, performing financial valuation analysis in the healthcare sector. She has experience working on a range of transactions in the healthcare and biotechnology sectors, including multi-billion dollar leveraged buyouts, initial public offerings and follow-on equity raises. Caroline graduated magna cum laude from Georgetown University with a Bachelor of Arts in Economics, a Pre-Medical concentration, and Cognitive Science minor.  

Doug Loe

Doug is Echelon Wealth Partners’ healthcare and biotechnology analyst, and has been recognized as one of Canada’s preeminent analysts by both Starmine and Brendan Wood International.  He has covered the Canadian biotechnology sector since 1999/2000, and focuses predominantly on publicly-traded Canadian healthcare firms, covering a broad spectrum of drug development, medical equipment/diagnostic development, and healthcare services firms. Doug holds a MBA from Queen’s University and a M.Sc and Ph.D in biochemistry from the University of Guelph.

Clarissa Desjardins

Mrs. Desjarding is the President and CEO of Clementia Pharmaceuticals Inc.  Previously, Clarissa was CEO at the Center of Excellence in Personalized Medicine, founder of Advanced Bioconcept and co-founded Caprion Pharmaceuticals Inc.

Clarissa received the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association, was nominated to Ernst &Young’s Entrepreneur of the Year award and was one of Canada’s top young Canadians likely to influence the future by the Globe and Mail.  She was a Board member of Genome Canada,. 

She earned a Ph.D. in Neurology and Neurosurgery from McGill’s Faculty of Medicine, and was a Medical Research Council postdoctoral fellow.

Steven Xanthoudakis

Dr. Steven Xanthoudakis has 24 years of experience in the Pharmaceutical industry. Since early 2007 he has been icoordinating Merck's Canadian and LATAM R&D out-reach programs. As Director, Business Development & Licensing for Merck Research Laboratories, his primary role is to build lasting relationships with the VCl, biotechnology and academic research communities. He currently manages Merck's Venture partnerships with Lumira Capital and Amorchem . He also the acting Chair of the CQDM Strategic Orientation Committee.  He received his doctoral degree from the Department of Microbiology and Immunology at McGill University. 

Steve Nagler

Steve Nagler co-founded MedPro Investors, LLC in 2013.  Mr. Nagler is also the Founder and Chairman of TriState Ventures, which was active in angel investing for over 20 years.  TriState now assists emerging companies in securing institutional investments and corporate partners. 

He is known as a skillful negotiator and strategist assisting clients in concluding agreements for financing, corporate partnering, acquisitions and various other growth strategies.  He is a frequent speaker at life science conferences and has written extensively on the biotech sector.

He is a Partner at Eaton & Van Winkle LLP, a highly regarded corporate law firm based in New York.

David Young

Dr. Young is a successful serial life science entrepreneur. He is a founder and the CEO of Actium Research. Previously he founded ARIUS Research, which was named a top 50 company by the TSX Venture Exchange, a top 10 company by Ottawa Life Sciences Council, and Biotech Company of the Year by Biotec Canada.

 

Dr. Young is founding Chairman of the Ontario Biosciences Innovation Organization. He is a director of MabNet, a director of the St. Michael’s Hospital Foundation and a director of BioCanRx.

 

He received his M.D., his M.Sc. and did his surgical and science training in the General Surgery and the Surgeon Scientist Program, all at the University of Toronto. He is the inventor or author on over 200 patents or scientific papers.

Philippe Douville

Dr. Douville is an executive with significant entrepreneurial experience in the biotechnology and pharmaceutical industries. He is founder and Chief Executive Officer of Milestone Pharmaceuticals Inc. While at Milestone, he raised $34 million in several rounds of equity financing with top tier life sciences venture capital firms to advance Milestone’s lead program from discovery to the clinic.

 

Prior to Milestone Pharmaceuticals, he held the positions of CEO and Chief Business Officer at Galileo Genomics (later Genizon Biosciences), a population genomics company he co-founded.

 

He has a Ph.D. in Neuroscience from McGill University and an MBA from the HEC business school of the University of Montreal.

Philippe Douville

Dr. Douville is an executive with significant entrepreneurial experience in the biotechnology and pharmaceutical industries. He is founder and Chief Executive Officer of Milestone Pharmaceuticals Inc. While at Milestone, he raised $34 million in several rounds of equity financing with top tier life sciences venture capital firms to advance Milestone’s lead program from discovery to the clinic.

 

Prior to Milestone Pharmaceuticals, he held the positions of CEO and Chief Business Officer at Galileo Genomics (later Genizon Biosciences), a population genomics company he co-founded.

 

He has a Ph.D. in Neuroscience from McGill University and an MBA from the HEC business school of the University of Montreal.

Michael Midmer

Michael has over 15 years of experience in the life science industry, business development and corporate finance. He is the CEO of Zucara Therapeutics and Vasomune Therapeutics through his role as Entrepreneur-in-Residence at MaRS Innovation. Before these roles, Michael spent 10 years in venture capital as Director at Rosetta Capital, managing over 30 investments in North America and Europe including exits such as Enobia, Cytochroma, Ambit and Resonant. In addition, Michael has been a board member for several companies and was the Chair of a not-for-profit board.

 

Michael has an MSc in molecular biology from the University of Toronto (Canada) and an MBA from Imperial College Business School (UK). 

Michael Midmer

Michael has over 15 years of experience in the life science industry, business development and corporate finance. He is the CEO of Zucara Therapeutics and Vasomune Therapeutics through his role as Entrepreneur-in-Residence at MaRS Innovation. Before these roles, Michael spent 10 years in venture capital as Director at Rosetta Capital, managing over 30 investments in North America and Europe including exits such as Enobia, Cytochroma, Ambit and Resonant. In addition, Michael has been a board member for several companies and was the Chair of a not-for-profit board.

 

Michael has an MSc in molecular biology from the University of Toronto (Canada) and an MBA from Imperial College Business School (UK). 

Anie Perrault

Anie Perrault is the Executive Manager of BIOQuébec and a part-time member (judge) at the Canadian Human Rights Tribunal.  She has over 25 years of professional experience in both the public and private sectors. A member of several boards notably, that of Loto-Québec, Genome Québec and the University of Sherbrooke. 

 

She held the position of Vice President of Communications at Génome Canada from 2001 to 2006 and prior to this, she was National Communications Director for Canada's Research-Based Pharmaceutical Companies (Rx&D), now Innovative Medicines Canada.

 

She completed her legal training at the École du Barreau du Québec in 1993 after having obtained her Bachelor of Civil Law from the University of Ottawa

Didier Leconte

Didier Leconte joined the Fonds de solidarité FTQ in December 2012 as Senior Director, Investments for the Life Sciences sector. During his career he has held various managing positions, all related to innovation.

 

From 2004 to 2012, he was a major player in the commercialization of university research in Québec. In 2004, he joined Gestion Univalor. In 2009, Didier Leconte became the CEO of MSBi Valorisation and in 2012, he arranged the merger with Valeo Management (now Aligo Innovation), of which he was the interim president. 

Mr. Leconte holds a degree in materials engineering as well as a Masters of Business Administration (MBA) specialized in technology management from UQAM-ESG.

Gautam Jaggi

 

Gautam Jaggi is a Director at EYQ, EY’s think tank for the 21st century. Founded in 2016, EYQ focuses on finding the upside of disruption by identifying disruptive trends and convening disparate voices.  Gautam leads EYQ’s overall perspective on disruptive innovation as well as on several "megatrends": Health Reimagined, The Future of Work, and Behavioral Revolution.

 

Prior to his role at EYQ, Gautam led the development of thought leadership for EY's Life Sciences and Health sectors. In this capacity, he served as the lead author and/or Managing Editor of Progressions (EY’s annual pharmaceutical industry report), Beyond Borders (EY’s annual biotechnology industry report) and Pulse of the Industry (EY’s annual medical technology report).

Gautam Jaggi

 

Gautam Jaggi is a Director at EYQ, EY’s think tank for the 21st century. Founded in 2016, EYQ focuses on finding the upside of disruption by identifying disruptive trends and convening disparate voices.  Gautam leads EYQ’s overall perspective on disruptive innovation as well as on several "megatrends": Health Reimagined, The Future of Work, and Behavioral Revolution.

 

Prior to his role at EYQ, Gautam led the development of thought leadership for EY's Life Sciences and Health sectors. In this capacity, he served as the lead author and/or Managing Editor of Progressions (EY’s annual pharmaceutical industry report), Beyond Borders (EY’s annual biotechnology industry report) and Pulse of the Industry (EY’s annual medical technology report).

Gautam Jaggi

 

Gautam Jaggi is a Director at EYQ, EY’s think tank for the 21st century. Founded in 2016, EYQ focuses on finding the upside of disruption by identifying disruptive trends and convening disparate voices.  Gautam leads EYQ’s overall perspective on disruptive innovation as well as on several "megatrends": Health Reimagined, The Future of Work, and Behavioral Revolution.

 

Prior to his role at EYQ, Gautam led the development of thought leadership for EY's Life Sciences and Health sectors. In this capacity, he served as the lead author and/or Managing Editor of Progressions (EY’s annual pharmaceutical industry report), Beyond Borders (EY’s annual biotechnology industry report) and Pulse of the Industry (EY’s annual medical technology report).

Lara Iob

 

Lara is a partner in the Assurance practice of EY, and has over 21 years of experience providing audit and audit-related services to both private and
public companies of various sizes.

 

While having spent most of her career in Montreal, she has also worked for several years in the Silicon Valley, California area.

 

Lara has spent the past 15 years focused on serving a multitude
of clients in the life sciences industry, and is the Quebec leader of the Life Sciences team, which forms part of the global life sciences network of EY.


She graduated from McGill University with a Bachelor of Commerce in 1995, and a Graduate Diploma in accountancy in 1997.

Yann Lavallée

 

Yann is a partner in the Assurance practice of EY, a global professional services firm, and has 19 years of experience providing audit and audit-related services to both private and public companies of various sizes. While having spent most of his career in Montreal, he has also worked in Belfast, Great Britain. 

 

Yann focuses on serving a multitude of clients mostly in the Life Sciences and Technology industries, and is a member of the Life Sciences and Technology teams at EY.

 

He graduated from HEC Montréal with a Bachelor in Business Administration in 1997, and a diploma in Public Accountancy in 1998.

Kelly Holman

 

Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry.

 

Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $300 million of venture capital and has been instrumental in deploying over $160 million across 28 investments. He currently serves on the Board of Directors of Functional Neuromodulation. He  also serves on the Board of Directors of the Ontario Bioscience Innovation Organization .

Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen's University.

Jean-Francois Pariseau

BIO coming soon.